Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

immune checkpoint inhibitor

  • You have access
    Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors
    NAR BAHADUR KATUWAL, NAHEE PARK, KAMAL PANDEY, MIN SIL KANG, SA DEOK HONG, MITHUN GHOSH, SEUL-GI KIM, YOUNG BIN CHO, JIN HUR, SEUNG KI KIM and YONG WHA MOON
    Anticancer Research January 2023, 43 (1) 85-95; DOI: https://doi.org/10.21873/anticanres.16137
  • You have access
    Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation
    SOU HATTORI, SHINICHIRO OKAUCHI, YUIKA SASATANI, GEN OHARA, KUNIHIKO MIYAZAKI, SHINYA SATO, TAKAHIDE KODAMA, TOSHIHIRO SHIOZAWA, HIROAKI SATOH and NOBUYUKI HIZAWA
    Anticancer Research September 2022, 42 (9) 4589-4595; DOI: https://doi.org/10.21873/anticanres.15962
  • You have access
    Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer
    SATOSHI INOUE, NAOTO SASSA, HIDEJI KAWANISHI, YURI YUGUCHI, TOMOHIDE SUZUKI, JUN NAGAYAMA, HIROTAKA MATSUI, YUDAI MIYATA, YUYA SOEDA, KOSUKE TOCHIGI, YUSHI YAMAUCHI, MOTOHIRO MAEDA, IKUO KOBAYASHI, RYOHEI HATTORI, YOSHIHISA MATSUKAWA and MASASHI KATO
    Anticancer Research July 2022, 42 (7) 3627-3636; DOI: https://doi.org/10.21873/anticanres.15851
  • You have access
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
    TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI and TAKASHI NAKAGAWA
    Anticancer Research July 2022, 42 (7) 3653-3664; DOI: https://doi.org/10.21873/anticanres.15854
  • Open Access
    Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer
    EISUKE BOOKA, HIROTOSHI KIKUCHI, RYOMA HANEDA, WATARU SONEDA, SANSHIRO KAWATA, TOMOHIRO MURAKAMI, TOMOHIRO MATSUMOTO, YOSHIHIRO HIRAMATSU and HIROYA TAKEUCHI
    Anticancer Research June 2022, 42 (6) 2977-2987; DOI: https://doi.org/10.21873/anticanres.15781
  • You have access
    Survival and Early Death Within Three Months from the Start of Immune Checkpoint Inhibitors in Patients With Different Types of Cancer
    CARSTEN NIEDER, SIV GYDA AANES and ELLINOR C. HAUKLAND
    Anticancer Research June 2022, 42 (6) 3061-3066; DOI: https://doi.org/10.21873/anticanres.15793
  • You have access
    Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer
    MOTOHIRO FUJIWARA, RYO FUJIWARA, TETSUYA URASAKI, TOMOHIKO OGUCHI, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, JUNJI YONESE and TAKESHI YUASA
    Anticancer Research April 2022, 42 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.15685
  • You have access
    Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
    CHIARA CICCARESE, ROBERTO IACOVELLI, SEBASTIANO BUTI, FRANCESCA PRIMI, SERENA ASTORE, FRANCESCO MASSARI, MIRIAM GRAZIA FERRARA, GIUSEPPE PALERMO, NAZARIO FOSCHI, VALERIO IACOVELLI, ERNESTO ROSSI, GIOVANNI SCHINZARI, PIERLUIGI BOVE, PIERFRANCESCO BASSI, EMILIO BRIA and GIAMPAOLO TORTORA
    Anticancer Research March 2022, 42 (3) 1487-1493; DOI: https://doi.org/10.21873/anticanres.15620
  • You have access
    Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma
    YUKARI BANDO, JUNYA FURUKAWA, YASUYOSHI OKAMURA, TAKUTO HARA, TOMOAKI TERAKAWA, YUZO NAKANO and MASATO FUJISAWA
    Anticancer Research February 2022, 42 (2) 973-979; DOI: https://doi.org/10.21873/anticanres.15557
  • You have access
    Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
    HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA and KATSUHIRO MIURA
    Anticancer Research December 2021, 41 (12) 6225-6230; DOI: https://doi.org/10.21873/anticanres.15442

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire